spacer
home > ebr > autumn 2017 > new strategy
PUBLICATIONS
European Biopharmaceutical Review

New Strategy

To move away from ‘all-comers’ trials, the early identification of genetic factors influencing effectiveness in patient subpopulations is key. A recent increase in the use of predictive human tissue models led to the idea for a nationwide multidisciplinary collaboration that combined assays in fresh, diseased human tissues studied ex vivo, with whole exome sequencing. This allowed genomic markers to be recognised, distinguishing patients identified by the human tissue assays as ‘good’ or ‘poor’ responders.

This Scottish pharmacogenomics project has made great strides in the understanding of chronic obstructive pulmonary disease (COPD) and inflammatory bowel diseases (IBD) by using whole exome sequencing, bioinformatics and fresh human tissue assays to relate drug response to genotype. The study findings underpin a new framework for patient stratification in clinical trials that combines in vitro and molecular informatics to improve pharma success rates and accelerate the availability of effective medications.

The most common cause of drug failure is poor efficacy at Phase 1 or 3, which is, in part, attributed to clinical trials of entire patient populations, including both ‘responders’ and ‘nonresponders’ (1,2). Precision medicine can improve the prediction of clinical efficacy by selecting only those patient subpopulations likely to gain clear benefit for trials, but such forecasts require methods to identify patient subpopulations at an early stage, ideally during preclinical testing (2-4). Human tissue data generated in early discovery via a wide range of models – including stem cells, fresh human tissues and pathological specimens – is increasingly being used in preclinical testing (5-7). Tissue samples collected from the target patient population allow researchers to directly test the effect of new drugs in systems that closely reflect the in vivo situation, providing an early prediction of efficacy. The responses of tissues from different patients when studied in vitro can vary considerably, reflecting the clinical reality of responders and non-responders.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
David Bunton is Chief Executive Officer of ReproCELL Europe. He is an experienced and respected human tissue pharmacologist and co-founder of Biopta, which merged with Reinnervate Ltd in July 2016 to form ReproCELL Europe.

Marian McNeil is Business Development Manager at Stratified Medicine Scotland – Innovation Centre. She has recently gained a master's degree in stratified medicine and pharmacological innovation from the University of Glasgow, Scotland, and has extensive experience in the medical marketing interface for oncology pipeline products.

Pamela Brankin joined Aridhia in 2011, taking on the role of Head of Marketing and Communications in 2015. She holds a BA Hons in English and French from the University of Dundee, UK, a postgraduate diploma in information technology from the University of St Andrews, UK, and an advanced diploma in professional French from the Chambre de Commerce et d'Industrie de Paris, France.

spacer
David Bunton
spacer
spacer
spacer
Marian McNeil
spacer
spacer
spacer
Pamela Brankin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

FlyPharma Conference Europe concludes its fourth successful year in Brussels, Belgium, 5-6 June 2018

The FlyPharma Conference Europe wrapped up for another year on 6 June, returning with an expanded roster of speakers who provided insight into all aspects of the pharmaceutical supply chain. The event was once again hosted at the Sheraton Brussels Airport Hotel and the Host Partner, Brussels Airport, as always provided speakers and insight into its own experiences working directly with a number of supply chain stakeholders.
More info >>

White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>

 
Industry Events

RDD Asia 2018

14-15 November 2018, Grand Hyatt Kochi, Kerala, India

A must-attend meeting for pulmonary and nasal researchers, inhaled product developers and vendors active in this important pharmaceutical niche.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement